Latest News and Press Releases

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to...

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and...

Fort Lauderdale, FL, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Anathapinkida Health’s line of detoxifying supplements has drawn positive attention from a growing audience of international consumers. It has...

Fort Lauderdale, FL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Anathapindika is already a popular wellness brand in other areas of the world, and now it will be bringing its innovative detoxifying...

Fort Lauderdale, FL, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Anathapindika Health is an innovative health and wellness brand dedicated to providing natural health solutions to those facing genuine health...

Fort Lauderdale, FL, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Anathapindika Health has been gaining a following in South Korea through its detoxifying nutraceutical formulas. From everyday consumers to...

RetinalGenix Technologies and RGEN Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases.

ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and...

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01...

ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for...